Phase 3 Readout
NRIX: Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref
June 1, 2032 · nx-5948. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- June 1, 2032
- Company
- Nurix Therapeutics, Inc. (NRIX)
- Drug
- nx-5948
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Open-label, Multicenter Study of NX-5948 Versus Pirtobrutinib in Relapsed/Ref
- Drug
- nx-5948
- Indication
- Small Lymphocytic Lymphoma; Chronic Lymphocytic Leukemia; B-cell Lymphoma